Glenmark receives US FDA nod for anti-inflammatory drug indomethacin

Glenmark Pharmaceuticals has been granted final approval by the US Food & Drug Administration (FDA) for indomethacin extended-release capsule (75 mg), the generic version of Indocin SR capsule of Iroko Pharmaceuticals LLC. Indomethacin is a non-steroidal anti-inflammatory drug commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation.

According to IMS Health sales data for the 12 month period ending April 2017, the Indocin SR extended-release capsule (75 mg) market achieved annual sales of approximately $ 6.3 million.

Glenmark’s current portfolio consists of 118 products authorised for distribution in the US marketplace and 67 ANDA’s pending approval